{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:49Z","timestamp":1793317609772,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.annonc.2026.04.016","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:06:56Z","timestamp":1777993616000},"page":"1157-1166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Survival outcomes in POD1UM-303\/InterAACT-2: a phase III study of retifanlimab plus carboplatin\u2013paclitaxel in first-line advanced squamous anal cancer"],"prefix":"10.1016","volume":"37","author":[{"given":"S.","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6997-6090","authenticated-orcid":false,"given":"E.","family":"Samalin-Scalzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Evesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-6346","authenticated-orcid":false,"given":"M.","family":"Ben Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Dhadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8344-1762","authenticated-orcid":false,"given":"R.","family":"Guimbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lievre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Maurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-5693","authenticated-orcid":false,"given":"C.","family":"de la Fouchardiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6554-5488","authenticated-orcid":false,"given":"M.","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Spano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2026.04.016_bib2","first-page":"924","article-title":"International trends in anal cancer incidence rates","volume":"46","author":"Islami","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.016_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CEJ.0000000000000842","article-title":"Global trends in anal cancer incidence and mortality","volume":"33","author":"Mignozzi","year":"2024","journal-title":"Eur J Cancer Prev"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.016_bib4","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3390\/curroncol30030246","article-title":"Anal cancer: the past, present and future","volume":"30","author":"Gondal","year":"2023","journal-title":"Curr Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.04.016_bib5","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.2012.45.2524","article-title":"Changing patterns of anal canal carcinoma in the United States","volume":"31","author":"Nelson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.016_bib6","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"22","key":"10.1016\/j.annonc.2026.04.016_bib7","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.04.016_bib8","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.3390\/curroncol30050343","article-title":"Immunotherapy in anal cancer","volume":"30","author":"Dhawan","year":"2023","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.016_bib9","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/2159-8290.CD-20-1760","article-title":"Tumor immunity and immunotherapy for HPV-related cancers","volume":"11","author":"Shamseddine","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.annonc.2026.04.016_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102254","article-title":"A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)","volume":"9","author":"Lakhani","year":"2024","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.annonc.2026.04.016_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100529","article-title":"A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao","year":"2022","journal-title":"ESMO Open"},{"issue":"10495","key":"10.1016\/j.annonc.2026.04.016_bib12","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(25)00631-2","article-title":"Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303\/InterAACT-2): a global, phase 3 randomised controlled trial","volume":"405","author":"Rao","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.016_bib14","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.016_bib15","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1080\/03610929108830654","article-title":"Correcting for non-compliance in randomized trials using rank preserving structural failure time models","volume":"20","author":"Robins","year":"1991","journal-title":"Commun Stat Theory Methods"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.016_bib16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.0006-341X.2000.00779.x","article-title":"Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests","volume":"56","author":"Robins","year":"2000","journal-title":"Biometrics"},{"issue":"5","key":"10.1016\/j.annonc.2026.04.016_bib17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"16 suppl","key":"10.1016\/j.annonc.2026.04.016_bib18","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2025.43.16_suppl.3525","article-title":"POD1UM-303\/INTERAACT2 subgroup analyses and impact of delayed retifanlimab treatment on outcomes in patients with squamous cell carcinoma of the anal canal (SCAC)","volume":"43","author":"Fakih","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.04.016_bib19","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.04.016_bib20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.04.016_bib21","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:00:20Z","timestamp":1786082420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426001766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0923753426001766"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.016","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes in POD1UM-303\/InterAACT-2: a phase III study of retifanlimab plus carboplatin\u2013paclitaxel in first-line advanced squamous anal cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}